
Moderna’s new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major trial, the company announced Monday. The vaccine, called mRNA-1010, was tested in a Phase 3 study in adults aged 50 and older. It worked better than a standard-dose flu vaccine, providing 26.6% more protection… read on > read on >